Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Polymer-Based Delivery of Peptide Drugs to Treat Diabetes: Normalizing Hyperglycemia and Preventing Diabetic Complications

Polymer-Based Delivery of Peptide Drugs to Treat Diabetes: Normalizing Hyperglycemia and... Diabetes is a serious metabolic disease in which chronic hyperglycemia results in diabetic microvascular and macrovascular complications from progressive vascular damage and dysfunction. Diabetes is life-threating and disabling, and is associated with costly complications and reduced life expectancy. Therefore, developing therapies for the treatment of diabetes is urgent and a significant challenge. Several peptides, including insulin, glucagon-like peptide-1, proinsulin C-peptide, and apelin, effectively normalize hyperglycemia and prevent hyperglycemia-induced diabetic complications, which are essential for the treatment of diabetes. However, a key limitation of peptide drugs for the clinical use is their short half-life. In this review, we describe the pathophysiological mechanisms and treatments of diabetic vascular complications. In addition, we discuss modification of peptide drugs by various approaches involving polymers to extend their blood circulating times and the use of the modified peptides in experimental and clinical studies. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png BioChip Journal Springer Journals

Polymer-Based Delivery of Peptide Drugs to Treat Diabetes: Normalizing Hyperglycemia and Preventing Diabetic Complications

Jeon, Hye-Yoon; Lee, Ah-Jun; Ha, Kwon-Soo
BioChip Journal , Volume 16 (2) – Jun 1, 2022
Download PDF
17 pages

Loading next page...
 
/lp/springer-journals/polymer-based-delivery-of-peptide-drugs-to-treat-diabetes-normalizing-i0LNITUhJV
Publisher
Springer Journals
Copyright
Copyright © The Korean BioChip Society 2022
ISSN
1976-0280
eISSN
2092-7843
DOI
10.1007/s13206-022-00057-0
Publisher site
See Article on Publisher Site

Abstract

Diabetes is a serious metabolic disease in which chronic hyperglycemia results in diabetic microvascular and macrovascular complications from progressive vascular damage and dysfunction. Diabetes is life-threating and disabling, and is associated with costly complications and reduced life expectancy. Therefore, developing therapies for the treatment of diabetes is urgent and a significant challenge. Several peptides, including insulin, glucagon-like peptide-1, proinsulin C-peptide, and apelin, effectively normalize hyperglycemia and prevent hyperglycemia-induced diabetic complications, which are essential for the treatment of diabetes. However, a key limitation of peptide drugs for the clinical use is their short half-life. In this review, we describe the pathophysiological mechanisms and treatments of diabetic vascular complications. In addition, we discuss modification of peptide drugs by various approaches involving polymers to extend their blood circulating times and the use of the modified peptides in experimental and clinical studies.

Journal

BioChip Journal – Springer Journals

Published: Jun 1, 2022

Keywords: Diabetes; Hyperglycemia; Diabetic complications; Peptides; Polymers

References

  • Mechanisms of diabetic complications
    Forbes, JM; Cooper, ME
  • Biochemistry and molecular cell biology of diabetic complications
    Brownlee, M
  • C-peptide replacement therapy as an emerging strategy for preventing diabetic vasculopathy
    Bhatt, MP; Lim, YC; Ha, KS
  • Estimating life years lost to diabetes: outcomes from analysis of national diabetes audit and office of national statistics data
    Heald, AH; Stedman, M; Davies, M; Livingston, M; Alshames, R; Lunt, M; Rayman, G; Gadsby, R
  • Pursuit of a perfect insulin
    Zaykov, AN; Mayer, JP; DiMarchi, RD
  • A depot-forming glucagon-like peptide-1 fusion protein reduces blood glucose for five days with a single injection
    Amiram, M; Luginbuhl, KM; Li, X; Feinglos, MN; Chilkoti, A
  • One-week glucose control via zero-order release kinetics from an injectable depot of glucagon-like peptide-1 fused to a thermosensitive biopolymer
    Luginbuhl, KM; Schaal, JL; Umstead, B; Mastria, EM; Li, XH; Banskota, S; Arnold, S; Feinglos, M; D'Alessio, D; Chilkoti, A
  • Fusion of fibroblast growth factor 21 to a thermally responsive biopolymer forms an injectable depot with sustained anti-diabetic action
    Gilroy, CA; Roberts, S; Chilkoti, A
  • Hundred years of insulin therapy: purified early insulins
    Lapolla, A; Dalfra, MG
  • Application of elastin-like biopolymer-conjugated C-peptide hydrogel for systemic long-term delivery against diabetic aortic dysfunction
    Lee, AJ; Lee, YJ; Jeon, HY; Kim, M; Han, ET; Park, WS; Hong, SH; Kim, YM; Ha, KS
  • Molecular and materials engineering for delivery of peptide drugs to treat type 2 diabetes
    Varanko, AK; Chilkoti, A
  • Genetically encoded elastin-like polypeptides for drug delivery
    Jenkins, IC; Milligan, JJ; Chilkoti, A
  • Long-acting C-peptide and neuropathy in type 1 diabetes: a 12-month clinical trial
    Wahren, J; Foyt, H; Daniels, M; Arezzo, JC
  • C-peptide protects against hyperglycemic memory and vascular endothelial cell apoptosis
    Bhatt, MP; Lee, YJ; Jung, SH; Kim, YH; Hwang, JY; Han, ET; Park, WS; Hong, SH; Kim, YM; Ha, KS
  • Oxidative Stress and Diabetic Complications
    Giacco, F; Brownlee, M
  • The vicious cycle between transglutaminase 2 and reactive oxygen species in hyperglycemic memory-induced endothelial dysfunction
    Lee, JY; Lee, YJ; Jeon, HY; Han, ET; Park, WS; Hong, SH; Kim, YM; Ha, KS
  • Reactive oxygen species mediate a cellular 'memory' of high glucose stress signalling
    Ihnat, MA; Thorpe, JE; Kamat, CD; Szabo, C; Green, DE; Warnke, LA; Lacza, Z; Cselenyak, A; Ross, K; Shakir, S; Piconi, L; Kaltreider, RC; Ceriello, A
  • Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells
    Du, X; Matsumura, T; Edelstein, D; Rossetti, L; Zsengeller, Z; Szabo, C; Brownlee, M
  • Epigenetic phenomena linked to diabetic complications
    Pirola, L; Balcerczyk, A; Okabe, J; El-Osta, A
  • Epigenetics mechanisms and implications for diabetic complications
    Cooper, ME; El-Osta, A
  • SIRT1, p66(Shc), and Set7/9 in vascular hyperglycemic memory
    Paneni, F; Volpe, M; Luscher, TF; Cosentino, F
  • Diabetic retinopathy, metabolic memory and epigenetic modifications
    Kowluru, RA
  • Progression of incipient diabetic retinopathy during good glycemic control
    Engerman, RL; Kern, TS
  • Realising the long-term promise of insulin therapy: the DCCT/EDIC study
    Nathan, DM
  • The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes
    King, P; Peacock, I; Donnelly, R
  • 10-year follow-up of intensive glucose control in type 2 diabetes
    Holman, RR; Paul, SK; Bethel, MA; Matthews, DR; Neil, HA
  • Global trends in diabetes complications: a review of current evidence
    Harding, JL; Pavkov, ME; Magliano, DJ; Shaw, JE; Gregg, EW
  • Interpreting global trends in type 2 diabetes complications and mortality
    Ali, MK; Pearson-Stuttard, J; Selvin, E; Gregg, EW
  • Current understanding of the molecular and cellular pathology of diabetic retinopathy
    Antonetti, DA; Silva, PS; Stitt, AW
  • Global prevalence of diabetic retinopathy and projection of burden through 2045 systematic review and meta-analysis
    Teo, ZL; Tham, YC; Yu, M; Chee, ML; Rim, TH; Cheung, N; Bikbov, MM; Wang, YX; Tang, YT; Lu, Y; Wong, IY; Ting, DSW; Tan, GSW; Jonas, JB; Sabanayagam, C; Wong, TY; Cheng, CY
  • Diabetic retinopathy in the context of patients with diabetes
    Simo-Servat, O; Hernandez, C; Simo, R
  • Essential role of transglutaminase 2 in vascular endothelial growth factor-induced vascular leakage in the retina of diabetic mice
    Lee, YJ; Jung, SH; Kim, SH; Kim, MS; Lee, S; Hwang, J; Kim, SY; Kim, YM; Ha, KS
  • Diabetic retinopathy: current understanding, mechanisms, and treatment strategies
    Duh, EJ; Sun, JK; Stitt, AW
  • Prevention of VEGF-mediated microvascular permeability by C-peptide in diabetic mice
    Lim, YC; Bhatt, MP; Kwon, MH; Park, D; Lee, S; Choe, J; Hwang, J; Kim, YM; Ha, KS
  • Cysteamine prevents vascular leakage through inhibiting transglutaminase in diabetic retina
    Lee, YJ; Jung, SH; Hwang, J; Jeon, S; Han, ET; Park, WS; Hong, SH; Kim, YM; Ha, KS
  • The benzodiazepine anesthetic midazolam prevents hyperglycemia-induced microvascular leakage in the retinas of diabetic mice
    Lee, YJ; Kim, M; Lee, JY; Jung, SH; Jeon, HY; Lee, SA; Kang, S; Han, ET; Park, WS; Hong, SH; Kim, YM; Ha, KS
  • Diabetic Retinopathy: Pathophysiology and Treatments
    Wang, W; Lo, ACY
  • Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence
    Simo, R; Hernandez, C
  • Ocular complications following intravitreal bevacizumab injection for retinopathy of prematurity and assessment of risk factors
    Bazvand, F; Riazi-Esfahani, H; Mirshahi, A; Khodabande, A; Khojastheh, H; Farahani, AD; Roohipourmoallai, R; Imani, M; Faghihi, H; Adib, NE; Bahar, MM
  • Diabetic retinopathy is a neurodegenerative disorder
    Lynch, SK; Abramoff, MD
  • The analysis of risk factors for diabetic nephropathy progression and the construction of a prognostic database for chronic kidney diseases
    Wang, G; Ouyang, J; Lie, S; Wang, H; Lian, BF; Liu, ZH; Xie, L
  • Silent diabetic nephropathy
    Said, SM; Nasr, SH
  • Diabetic kidney disease: An overview of prevalence, risk factors, and biomarkers
    Hussain, S; Jamali, MC; Habib, A; Hussain, MS; Akhtar, M; Najmi, AK
  • Midazolam ameliorates hyperglycemia-induced glomerular endothelial dysfunction by inhibiting transglutaminase 2 in diabetes
    Seo, J-A; Sayyed, ND; Lee, Y-J; Jeon, H-Y; Kim, E-B; Hong, S-H; Cho, S; Kim, M; Ha, K-S
  • Microvascular dysfunction and hyperglycemia: a vicious cycle with widespread consequences
    Stehouwer, CDA
  • Vascular permeability: regulation pathways and role in kidney diseases
    Cai, A; Chatziantoniou, C; Calmont, A
  • Extracellular matrix in kidney fibrosis: more than just a scaffold
    Bulow, RD; Boor, P
  • Transglutaminase 2 as a novel target in chronic kidney disease-methods, mechanisms and pharmacological inhibition
    Prat-Duran, J; Pinilla, E; Norregaard, R; Simonsen, U; Buus, NH
  • Treatment of renal fibrosis-turning challenges into opportunities
    Klinkhammer, BM; Goldschmeding, R; Floege, J; Boor, P
  • Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy
    Sloan, G; Selvarajah, D; Tesfaye, S
  • The Clinical potential of C-peptide replacement in type 1 diabetes
    Wahren, J; Kallas, A; Sima, AAF
  • Epidemiology of peripheral neuropathy and lower extremity disease in diabetes
    Hicks, CW; Selvin, E
  • Diabetic neuropathy: a position statement by the american diabetes association
    Pop-Busui, R; Boulton, AJ; Feldman, EL; Bril, V; Freeman, R; Malik, RA; Sosenko, JM; Ziegler, D
  • Proinsulin C-peptide prevents impaired wound healing by activating angiogenesis in diabetes
    Lim, YC; Bhatt, MP; Kwon, MH; Park, D; Na, S; Kim, YM; Ha, KS
  • Abnormal cell responses and role of TNF-alpha in impaired diabetic wound healing
    Xu, FX; Zhang, CY; Graves, DT
  • Current aspects in the pathophysiology and treatment of chronic wounds in diabetes mellitus
    Tsourdi, E; Barthel, A; Rietzsch, H; Reichel, A; Bornstein, SR
  • Mechanistic insight into diabetic wounds: pathogenesis, molecular targets and treatment strategies to pace wound healing
    Patel, S; Srivastava, S; Singh, MR; Singh, D
  • Topical epidermal growth factor spray for the treatment of chronic diabetic foot ulcers: a phase III multicenter, double-blind, randomized, placebo-controlled trial
    Park, KH; Han, SH; Hong, JP; Han, SK; Lee, DH; Kim, BS; Ahn, JH; Lee, JW
  • Co-delivery of a growth factor and a tissue-protective molecule using elastin biopolymers accelerates wound healing in diabetic mice
    Devalliere, J; Dooley, K; Hu, Y; Kelangi, SS; Uygun, BE; Yarmush, ML
  • Diabetes mellitus contributes to idiopathic pulmonary fibrosis: a review from clinical appearance to possible pathogenesis
    Wang, DG; Ma, Y; Tong, X; Zhang, YG; Fan, H
  • Diabetes and lung disease: an underestimated relationship
    Khateeb, J; Fuchs, E; Khamaisi, M
  • The diabetic lung–a new target organ?
    Pitocco, D; Fuso, L; Conte, EG; Zaccardi, F; Condoluci, C; Scavone, G; Incalzi, RA; Ghirlanda, G
  • Idiopathic pulmonary fibrosis and diabetes mellitus: a meta-analysis and systematic review
    Bai, L; Li, Z; Pan, TY; Wang, W; Wang, DA; Turner, C; Zhou, XM; He, HL
  • Idiopathic pulmonary fibrosis
    Richeldi, L; Collard, HR; Jones, MG
  • Proinsulin C-peptide prevents hyperglycemia-induced vascular leakage and metastasis of melanoma cells in the lungs of diabetic mice
    Jeon, HY; Lee, YJ; Kim, YS; Kim, SY; Han, ET; Park, WS; Hong, SH; Kim, YM; Ha, KS
  • Prevalence of cardiovascular disease and associated factors among type 2 diabetes patients in selected hospitals of Harari Region Eastern Ethiopia
    Regassa, LD; Tola, A; Ayele, Y
  • Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017
    Einarson, TR; Acs, A; Ludwig, C; Panton, UH
  • Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the fenofibrate intervention and event lowering in diabetes (FIELD) study
    Drury, PL; Ting, R; Zannino, D; Ehnholm, C; Flack, J; Whiting, M; Fassett, R; Ansquer, JC; Dixon, P; Davis, TME; Pardy, C; Colman, P; Keech, A
  • Novel treatments for cardiovascular disease prevention
    Huffman, MD; Bhatnagar, D
  • Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
    Birkeland, KI; Jorgensen, ME; Carstensen, B; Persson, F; Gulseth, HL; Thuresson, M; Fenici, P; Nathanson, D; Nystrom, T; Eriksson, JW; Bodegard, J; Norhammar, A
  • Canagliflozin and cardiovascular and renal events in type 2 diabetes
    Neal, B; Perkovic, V; Mahaffey, KW; de Zeeuw, D; Fulcher, G; Erondu, N; Shaw, W; Law, G; Desai, M; Matthews, DR; Grp, CPC
  • C-peptide prevents hyperglycemia-induced endothelial apoptosis through inhibition of reactive oxygen species-mediated transglutaminase 2 activation
    Bhatt, MP; Lim, YC; Hwang, J; Na, S; Kim, YM; Ha, KS
  • Polymer-based nanoparticles for oral insulin delivery: revisited approaches
    Fonte, P; Araujo, F; Silva, C; Pereira, C; Reis, S; Santos, HA; Sarmento, B
  • Peptide-modified biopolymers for biomedical applications
    Hersh, J; Broyles, D; Capcha, JMC; Dikici, E; Shehadeh, LA; Daunert, S; Deo, S
  • Protein PEGylation: an overview of chemistry and process considerations
    Damodaran, VB; Fee, CJ
  • FcRn: the neonatal Fc receptor comes of age
    Roopenian, DC; Akilesh, S
  • Insulin prevents pulmonary vascular leakage by inhibiting transglutaminase 2 in diabetic mice
    Jeon, HY; Seo, JA; Jung, SH; Lee, YJ; Han, ET; Park, WS; Hong, SH; Kim, YM; Ha, KS
  • Clinical pharmacokinetics and pharmacodynamics of insulin glulisine
    Becker, RHA; Frick, AD
  • Preparation of selenoinsulin as a long-lasting insulin analogue
    Arai, K; Takei, T; Okumura, M; Watanabe, S; Amagai, Y; Asahina, Y; Moroder, L; Hojo, H; Inaba, K; Iwaoka, M
  • Insulin glargine
    Bolli, GB; Owens, DR
  • Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes
    Klein, O; Lynge, J; Endahl, L; Damholt, B; Nosek, L; Heise, T
  • A review of the pharmacological properties of insulin degludec and their clinical relevance
    Haahr, H; Heise, T
  • Basal insulin peglispro: overview of a novel long-acting insulin with reduced peripheral effect resulting in a hepato-preferential action
    Jacober, SJ; Prince, MJ; Beals, JM; Hartman, ML; Qu, Y; Linnebjerg, H; Garhyan, P; Haupt, A
  • Insulin delivery methods: Past, present and future
    Shah, RB; Patel, M; Maahs, DM; Shah, VN
  • Oral insulin delivery platforms: strategies to address the biological barriers
    Xiao, YF; Tang, ZM; Wang, JQ; Liu, C; Kong, N; Farokhzad, OC; Tao, W
  • Oral insulin delivery: existing barriers and current counter-strategies
    Gedawy, A; Martinez, J; Al-Salami, H; Dass, CR
  • A review of GLP-1 receptor agonists in type 2 diabetes: a focus on the mechanism of action of once-weekly agents
    Cornell, S
  • GLP-1 receptor agonists: an updated review of head-to-head clinical studies
    Trujillo, JM; Nuffer, W; Smith, BA
  • Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1
    Jang, HJ; Kokrashvili, Z; Theodorakis, MJ; Carlson, OD; Kim, BJ; Zhou, J; Kim, HH; Xu, X; Chan, SL; Juhaszova, M; Bernier, M; Mosinger, B; Margolskee, RF; Egan, JM
  • Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein
    Glaesner, W; Vick, AM; Millican, R; Ellis, B; Tschang, SH; Tian, Y; Bokvist, K; Brenner, M; Koester, A; Porksen, N; Etgen, G; Bumol, T
  • Liraglutide
    Drucker, DJ; Dritselis, A; Kirkpatrick, P
  • Advances in biological functions and clinical studies of FGF21
    Lin, W; Zhang, TL; Zhou, YY; Zheng, JY; Lin, ZL
  • Fibroblast growth factor 21: a versatile regulator of metabolic homeostasis
    BonDurant, LD; Potthoff, MJ
  • Thermo-reversible injectable gel based on enzymatically-chopped low molecular weight methylcellulose for exenatide and FGF 21 delivery to treat types 1 and 2 diabetes
    Kim, JK; Yoo, C; Cha, YH; Kim, YH
  • A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis
    Pan, Q; Lin, S; Li, Y; Liu, L; Li, X; Gao, X; Yan, J; Gu, B; Chen, X; Li, W; Tang, T; Chen, C; Guo, L
  • AKR-001, an Fc-FGF21 analog, showed sustained pharmacodynamic effects on insulin sensitivity and lipid metabolism in type 2 diabetes patients
    Kaufman, A; Abuqayyas, L; Denney, WS; Tillman, EJ; Rolph, T
  • A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects
    Talukdar, S; Zhou, Y; Li, D; Rossulek, M; Dong, J; Somayaji, V; Weng, Y; Clark, R; Lanba, A; Owen, BM; Brenner, MB; Trimmer, JK; Gropp, KE; Chabot, JR; Erion, DM; Rolph, TP; Goodwin, B; Calle, RA
  • Pegbelfermin (BMS-986036), PEGylated FGF21, in patients with obesity and type 2 diabetes: results from a randomized phase 2 study
    Charles, ED; Neuschwander-Tetri, BA; Pablo Frias, J; Kundu, S; Luo, Y; Tirucherai, GS; Christian, R
  • Insulin biosynthesis: evidence for a precursor
    Steiner, DF; Cunningham, D; Spigelman, L; Aten, B
  • C-peptide as a therapeutic tool in diabetic nephropathy
    Hills, CE; Brunskill, NJ; Squires, PE
  • Preventive effects of thermosensitive biopolymer-conjugated C-peptide against high glucose-induced endothelial cell dysfunction
    Jung, SH; Lee, JY; Lee, SH; Kwon, MH; Han, ET; Park, WS; Hong, SH; Kim, YM; Ha, KS
  • Array-based high-throughput analysis of silk-elastinlike protein polymer degradation and c-peptide release by proteases
    Jeon, HY; Jung, SH; Jung, YM; Kim, YM; Ghandehari, H; Ha, KS
  • Novel formulations of C-peptide with long-acting therapeutic potential for treatment of diabetic complications
    Zashikhina, N; Sharoyko, V; Antipchik, M; Tarasenko, I; Anufrikov, Y; Lavrentieva, A; Tennikova, T; Korzhikova-Vlakh, E
  • Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor
    Tatemoto, K; Hosoya, M; Habata, Y; Fujii, R; Kakegawa, T; Zou, MX; Kawamata, Y; Fukusumi, S; Hinuma, S; Kitada, C; Kurokawa, T; Onda, H; Fujino, M
  • Effects of apelin peptides on diabetic complications
    Chen, H; Liu, C; Cheng, C; Zheng, L; Huang, K
  • The apelin receptor: physiology, pathology, cell signalling, and ligand modulation of a peptide-activated class A GPCR
    Chapman, NA; Dupre, DJ; Rainey, JK
  • Apelin inhibits the development of diabetic nephropathy by regulating histone acetylation in Akita mouse
    Chen, H; Li, J; Jiao, L; Petersen, RB; Li, J; Peng, A; Zheng, L; Huang, K
  • Fc-apelin fusion protein attenuates lipopolysaccharide-induced liver injury in mice
    Zhou, H; Yang, R; Wang, W; Xu, F; Xi, Y; Brown, RA; Zhang, H; Shi, L; Zhu, D; Gong, DW
  • Hepatic and cardiac beneficial effects of a long-acting Fc-apelin fusion protein in diet-induced obese mice
    Wang, W; Zhang, D; Yang, R; Xia, W; Qian, K; Shi, Z; Brown, R; Zhou, H; Xi, Y; Shi, L; Chen, L; Xu, F; Sun, X; Zhu, D; Gong, DW
  • Apelin-36 modulates blood glucose and body weight independently of canonical APJ receptor signaling
    Galon-Tilleman, H; Yang, H; Bednarek, MA; Spurlock, SM; Paavola, KJ; Ko, B; To, C; Luo, J; Tian, H; Jermutus, L; Grimsby, J; Rondinone, CM; Konkar, A; Kaplan, DD
  • Elevation of serum apelin-13 associated with proliferative diabetic retinopathy in type 2 diabetic patients
    Du, JH; Li, X; Li, R; Xu, L; Ma, RR; Liu, SF; Zhang, Z; Sun, HZ
  • Amelioration of sensory nerve dysfunction by C-Peptide in patients with type 1 diabetes
    Ekberg, K; Brismar, T; Johansson, BL; Jonsson, B; Lindstrom, P; Wahren, J
  • C-peptide activates AMPKalpha and prevents ROS-mediated mitochondrial fission and endothelial apoptosis in diabetes
    Bhatt, MP; Lim, YC; Kim, YM; Ha, KS